Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: A critical appraisal

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The use of drug-eluting stents (DES) in aortocoronary saphenous vein bypass grafts (SVGs) remains controversial. We reviewed 14 published studies that examined the outcomes after DES implantation in SVG lesions. All studies, except two, were retrospective, and reported follow-up for approximately 1 year or less. Ten of the 14 studies were single-center. Six studies (5 retrospective and 1 prospective), including a total of 711 patients, compared DES with bare metal stents: 2 studies included paclitaxel-eluting stents, 2 studies included sirolimus-eluting stents, and 2 studies included both. Four of five retrospective comparative studies showed lower incidence of major adverse cardiac events in the DES group during short-term follow-up (6-12 months), mainly due to a reduction in target vessel revascularization (TVR) (3 of 4 studies had high rates of follow-up angiography). In the only published prospective, randomized controlled study, patients receiving DES had lower incidence of TVR at 6 months, but during longer follow-up (median 32 months), they had similar incidence of TVR and higher mortality. A large, multicenter, randomized controlled clinical trial is needed to clarify the role of DES in the percutaneous treatment of SVG lesions.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalJournal of Interventional Cardiology
Volume21
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

Drug-Eluting Stents
Saphenous Vein
Coronary Artery Bypass
Transplants
Stents
Incidence
Retrospective Studies
Sirolimus
Paclitaxel
Angiography
Randomized Controlled Trials
Metals
Outcome Assessment (Health Care)
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{ece478d1fb364051aeaa48ef259d443a,
title = "Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: A critical appraisal",
abstract = "The use of drug-eluting stents (DES) in aortocoronary saphenous vein bypass grafts (SVGs) remains controversial. We reviewed 14 published studies that examined the outcomes after DES implantation in SVG lesions. All studies, except two, were retrospective, and reported follow-up for approximately 1 year or less. Ten of the 14 studies were single-center. Six studies (5 retrospective and 1 prospective), including a total of 711 patients, compared DES with bare metal stents: 2 studies included paclitaxel-eluting stents, 2 studies included sirolimus-eluting stents, and 2 studies included both. Four of five retrospective comparative studies showed lower incidence of major adverse cardiac events in the DES group during short-term follow-up (6-12 months), mainly due to a reduction in target vessel revascularization (TVR) (3 of 4 studies had high rates of follow-up angiography). In the only published prospective, randomized controlled study, patients receiving DES had lower incidence of TVR at 6 months, but during longer follow-up (median 32 months), they had similar incidence of TVR and higher mortality. A large, multicenter, randomized controlled clinical trial is needed to clarify the role of DES in the percutaneous treatment of SVG lesions.",
author = "Brilakis, {Emmanouil S.} and Bilal Saeed and Subhash Banerjee",
year = "2008",
month = "4",
doi = "10.1111/j.1540-8183.2007.00341.x",
language = "English (US)",
volume = "21",
pages = "151--157",
journal = "Journal of Interventional Cardiology",
issn = "0896-4327",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions

T2 - A critical appraisal

AU - Brilakis, Emmanouil S.

AU - Saeed, Bilal

AU - Banerjee, Subhash

PY - 2008/4

Y1 - 2008/4

N2 - The use of drug-eluting stents (DES) in aortocoronary saphenous vein bypass grafts (SVGs) remains controversial. We reviewed 14 published studies that examined the outcomes after DES implantation in SVG lesions. All studies, except two, were retrospective, and reported follow-up for approximately 1 year or less. Ten of the 14 studies were single-center. Six studies (5 retrospective and 1 prospective), including a total of 711 patients, compared DES with bare metal stents: 2 studies included paclitaxel-eluting stents, 2 studies included sirolimus-eluting stents, and 2 studies included both. Four of five retrospective comparative studies showed lower incidence of major adverse cardiac events in the DES group during short-term follow-up (6-12 months), mainly due to a reduction in target vessel revascularization (TVR) (3 of 4 studies had high rates of follow-up angiography). In the only published prospective, randomized controlled study, patients receiving DES had lower incidence of TVR at 6 months, but during longer follow-up (median 32 months), they had similar incidence of TVR and higher mortality. A large, multicenter, randomized controlled clinical trial is needed to clarify the role of DES in the percutaneous treatment of SVG lesions.

AB - The use of drug-eluting stents (DES) in aortocoronary saphenous vein bypass grafts (SVGs) remains controversial. We reviewed 14 published studies that examined the outcomes after DES implantation in SVG lesions. All studies, except two, were retrospective, and reported follow-up for approximately 1 year or less. Ten of the 14 studies were single-center. Six studies (5 retrospective and 1 prospective), including a total of 711 patients, compared DES with bare metal stents: 2 studies included paclitaxel-eluting stents, 2 studies included sirolimus-eluting stents, and 2 studies included both. Four of five retrospective comparative studies showed lower incidence of major adverse cardiac events in the DES group during short-term follow-up (6-12 months), mainly due to a reduction in target vessel revascularization (TVR) (3 of 4 studies had high rates of follow-up angiography). In the only published prospective, randomized controlled study, patients receiving DES had lower incidence of TVR at 6 months, but during longer follow-up (median 32 months), they had similar incidence of TVR and higher mortality. A large, multicenter, randomized controlled clinical trial is needed to clarify the role of DES in the percutaneous treatment of SVG lesions.

UR - http://www.scopus.com/inward/record.url?scp=41849121232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849121232&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8183.2007.00341.x

DO - 10.1111/j.1540-8183.2007.00341.x

M3 - Article

C2 - 18312303

AN - SCOPUS:41849121232

VL - 21

SP - 151

EP - 157

JO - Journal of Interventional Cardiology

JF - Journal of Interventional Cardiology

SN - 0896-4327

IS - 2

ER -